Home / News / ReVia Can Lead to Remission in Crohn’s Disease

ReVia Can Lead to Remission in Crohn’s Disease

Vivitrol or ReVia enabled 50 percent of patients with Crohn’s disease go into remission
Reviewed By: Joseph V. Madia, MD
By: Staff

2.9375
 






 




Traditional treatments for Crohn’s disease are effective at reducing inflammation by affecting the immune system.  The side effects can be difficult for many patients. A new study shows that a drug used to treat alcoholics may be effective without causing side effects.

Naltrexone (Vivitrol, ReVia and Depade) is approved by the FDA for treating alcohol dependence. A new Penn State College of Medicine study suggests an that  an off label use for naltrexone could help bring Crohn’s disease into remission. Fifty percent of patients taking naltrexone for a 24 week period saw their Crohn’s disease go into remission.

If you have Crohn’s disease, ask your doctor if off label use of naltrexone is appropriate.

Jill P. Smith, M.D., professor of medicine at Penn State College of Medicine explains the reasoning in trying naltrexone to treat Crohn’s disease. Researchers hypothesized that since endorphins and enkephalins (part of the opioid system) are involved in inflammatory bowel disease (IBD), causing interference with an opioid receptor could lead to a reversal of Crohn’s disease. 

Forty patients were used in this study, half of whom received naltrexone for 12 weeks and the other half received a placebo.

There was no difference in their Crohn’s disease at the four and eight week mark, but at 12 weeks, 70 percent experienced at least a 70-point decline in the Crohn’s Disease Activity Index (CDAI) score and healing of the colon was observed via colonoscopy.

Participants who continued use of naltrexone for an additional 12 weeks (24 total weeks) had a further 75-point decline in CDAI scores, which led to remission  in 50 percent of the participants.

Crohn’s Disease

Half a million people in the United States suffer from Crohn’s disease, usually appearing in the second and third decades of life, or the sixth and seventh. It is an inflammatory bowel disease caused by an auto-immune response, affecting any part of the digestive tract from the mouth to the anus.

Symptoms range from mild to severe, and are primarily digestive in nature, with common symptoms being fever, abdominal pain, persistent diarrhea, painful bowel movements, constipation and loss of appetite. Other symptoms such as skin ulcers, joint pain, eye inflammation (uveitis), mouth ulcers, and even neurological symptoms (seizures, headache, neuropathy) are present in some patients. Malnutrition and intestinal complications are common, with many patients experiencing fistulae, adhesions, and infections that may require surgery to treat. The risk of colon and intestinal cancer is increased.

 

Review
Reviewed by:

Joseph V. Madia, MD

Review Date: 
Friday May 20, 2011

Last Updated:
Tuesday June 21, 2011

Source: dailyRx